Drugs / GEn
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00311363 | Apr 2006 → Nov 2007 | restless legs syndrome | XenoPort, Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEn | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00311363 ↗ |
| Route | Oral | “1200 mg GEn (XP13512) orally, once daily for 24 weeks” NCT00311363 ↗ |